HemoGenyx: Funding, Investors & Team (Sep 2026)
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
HemoGenyx has raised $9.9M across 7 funding rounds on record, the most recent an undisclosed round of $4.1M announced in Apr 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
HemoGenyx Company Profile and Key Stats
Latest funding round on record: Apr 2026.
HemoGenyx Funding Rounds
HemoGenyx raised $830k in an undisclosed round announced in Sep 2023.
1.2 years later, an undisclosed round of $770k was announced in Nov 2024.
2 months later, an undisclosed round of $420k was announced in Jan 2025.
6 months later, an undisclosed round of $330k was announced in Jul 2025.
5 months later, an undisclosed round of $250k was announced in Dec 2025.
2 months later, an undisclosed round of $3.2M was announced in Feb 2026.
2 months later, an undisclosed round of $4.1M was announced in Apr 2026.
HemoGenyx Founders and Leadership Team
Contact details for the HemoGenyx team: 1 of 1 has an email address on file.
Start 14-day free trial →HemoGenyx Funding Compared to Other Biotechnology Startups
HemoGenyx's latest round of $4.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like HemoGenyx in Biotechnology and London
Companies Similar to HemoGenyx
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
HemoGenyx Funding FAQs
What does HemoGenyx do?
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
How much funding has HemoGenyx raised?
HemoGenyx has raised $9.9M across 7 rounds on record. The most recent is an undisclosed round of $4.1M announced in Apr 2026.
When did HemoGenyx last raise funding?
HemoGenyx's most recent funding round on record is an undisclosed round of $4.1M, announced in Apr 2026.
Who founded HemoGenyx?
FundedIQ lists Vladislav Sandler (Founder) at HemoGenyx.
Where is HemoGenyx headquartered?
HemoGenyx is based in London, England, United Kingdom.
How many employees does HemoGenyx have?
HemoGenyx is in the 11-50 employee band.
How does HemoGenyx's funding compare to other Biotechnology startups?
HemoGenyx's latest round of $4.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's HemoGenyx Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for HemoGenyx is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.